Matches in Nanopublications for { ?s ?p "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 9 of
9
with 100 items per page.
- NP873512.RAvprPeRqdyvYpM1HnBLRshwDkYVrPzGTOuUNClL1UicE130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP873512.RAvprPeRqdyvYpM1HnBLRshwDkYVrPzGTOuUNClL1UicE130_provenance.
- NP471528.RAJJAumaG03CkG7L9GqCYNaLMf_58ow8w1rKlC1p4b-44130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP471528.RAJJAumaG03CkG7L9GqCYNaLMf_58ow8w1rKlC1p4b-44130_provenance.
- assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1404179.RARfz1LssFmMoLDJhYzh686WUqt_vkAksbLqqVRoJd8Nw130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404179.RARfz1LssFmMoLDJhYzh686WUqt_vkAksbLqqVRoJd8Nw130_provenance.
- NP493145.RA8x4x3DzVRuciTJP7gbDXFEBfNehkaixkjs0gY5bfhtM130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493145.RA8x4x3DzVRuciTJP7gbDXFEBfNehkaixkjs0gY5bfhtM130_provenance.
- NP493142.RAOWHUrScQstVKe2VosNApBOckN3oqGq1vH1ZM9Tdq_2s130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493142.RAOWHUrScQstVKe2VosNApBOckN3oqGq1vH1ZM9Tdq_2s130_provenance.
- NP1404173.RAH_XBz4ufHQXUw6osx-ZB3n3wdBpFVxZJwlmz6EBS_V4130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404173.RAH_XBz4ufHQXUw6osx-ZB3n3wdBpFVxZJwlmz6EBS_V4130_provenance.
- NP1404178.RALiA-nWzGTst8QrpHJtsEekG4Z7eZ9oJaCiKBbC6dbnk130_assertion description "[Treatment with high-dose bolus IL-2 mediates complete cancer regression in approximately 8% of patients with metastatic renal cancer and melanoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1404178.RALiA-nWzGTst8QrpHJtsEekG4Z7eZ9oJaCiKBbC6dbnk130_provenance.